

NIH/NHLBI-funded PACT group announces the renewal of Production Assistance for Cellular Therapies (PACT)

The National Heart, Lung, and Blood Institute (NHLBI) is pleased to announce the renewal of the Production Assistance for Cellular Therapies (PACT) program. Five (5) Cell Processing Facilities: Center for Cell and Gene Therapy, Baylor College of Medicine; Center for Biomedicine and Genetics, City of Hope; Interdisciplinary Stem Cell Institute Cellular Manufacturing Program, University of Miami, Miller School of Medicine; Moffitt Cancer Center and Research Institute; University of Minnesota, Molecular and Cellular Therapeutics; and a Coordinating Center, The Emmes Corporation, were each awarded a five year contract. “We are very excited with continuing to support the cell therapy community and implementing new initiatives aimed at advancing the development of new cell therapies,” says NHLBI Project Director Lis Welniak, PhD.

PACT’s objective is to promote the advancement of cellular therapy research in the areas of regeneration of damaged/diseased tissues, organs, and biologic systems, and targeted treatments for serious diseases without effective therapies in support of the NHLBI. PACT will support translational research of novel cell therapies that advance the field of cellular therapy in order to enable scientifically meritorious translational science research to progress along IND-enabling pathways.

Applications

PACT will be accepting request for service applications beginning February 01, 2017. Visit the PACT website at www.pactgroup.net for more information and updates regarding applications.

About PACT

The PACT program is an NHLBI-funded initiative that is committed to the advancement of effective cell therapies. PACT supports the development of novel cell therapy products by providing production assistance to the cell therapy community, as well as educational training via web seminars. Production assistance is provided through the funded contract manufacturing of therapeutic cell products at PACT processing facilities. These facilities offer scale-up capability and expertise in the translational development needed to produce cell therapy products under cGMP and cGTP regulations. PACT’s educational training focuses on: translational development/scale-up and manufacture of cell therapy products, and quality assurance and regulatory issues.

Contact:

PACT
The Emmes Corporation, Rockville, MD
Debbie Wood or Laarni Ibenana
phone: 301-251-1161
email: pactinfo@pactgroup.net



TELEGRAFT

This project has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN268201600020C